Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 7Radiotherapy 6Vincristine 5Etoposide 5Cyclophosphamide 5Cisplatin 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Doxorubicin 4Carboplatin 4Capecitabine 4pembrolizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Prednisone 3Oxaliplatin 3Methotrexate 3Leucovorin 3Fluorouracil 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Surgical Procedures, Operative 2Ramucirumab 2Radiation 2Pemetrexed 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NETWORK × cemiplimab × Clear all
NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡